Blood · 2000 · 408 citations · 35 references
MedicineHematologyOncologyCancer ImmunologyCellular ImmunologyMolecular OncologyCell-mediated ImmunityCytotoxic T Lymphocyte ResponsesHematologic Malignancy TherapyMyeloid-derived Suppressor CellsT Cell BiologyCd34 Positive SelectionEliminationT Cell-mediated Cytotoxicity
Hematologic malignancies such as acute and chronic myeloid leukemia are characterized by the malignant transformation of immature CD34(+) progenitor cells. Transformation is associated with elevated expression of the Wilm's tumor gene encoded transcription factor (WT1). Here we demonstrate that WT1 can serve as a target for cytotoxic T lymphocytes (CTL) with exquisite specificity for leukemic progenitor cells. HLA-A0201- restricted CTL specific for WT1 kill leukemia cell lines and inhibit colony formation by transformed CD34(+) progenitor cells isolated from patients with chronic myeloid leukemia (CML), whereas colony formation by normal CD34(+) progenitor cells is unaffected. Thus, the tissue-specific transcription factor WT1 is an ideal target for CTL-mediated purging of leukemic progenitor cells in vitro and for antigen-specific therapy of leukemia and other WT1-expressing malignancies in vivo.
35
Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome
CB Lozzio, BB Lozzio · Blood · 1975 · 2.8K citations
Medicine, Hematology, Oncology +14
Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome
CB Lozzio, BB Lozzio · Blood · 1975 · 2.3K citations · Full text
Medicine, Hematology, Oncology +14
H-J Kolb, J. Mittermüller, Ch. Clemm et al. · Blood · 1990 · 1.5K citations · Full text
Medicine, Hematology, Oncology +16
A newly discovered class of human hematopoietic cells with SCID-repopulating activity
Mickie Bhatia, Dominique Bonnet, Barbara Murdoch et al. · Nature Medicine · 1998 · 614 citations